Tirzepatide
What is tirzepatide?
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. These receptors respond to hormones involved in blood sugar and appetite. Research vials are not the medicine formulations used in human trials.
Last updated: 2026-10-08
At a Glance
IN THIS ARTICLE
Why is Tirzepatide studied?
Tirzepatide is studied for activity at two incretin receptors. Incretins are hormones involved in responses to food. The two targets are GIP and GLP-1.
SURPASS studies focus on type 2 diabetes. SURMOUNT studies examine obesity and related outcomes. Each program uses defined clinical preparations.
The dual-target design raises questions about how the two signals interact. It does not prove synergy in every model. Nor does it make trial findings transferable to a catalog vial.
How does Tirzepatide work in research models?
Tirzepatide is a synthetic peptide with 39 amino acids. It is designed to activate GIP and GLP-1 receptors. These receptors can influence signals within cells.
Adipose tissue means body fat tissue. Pancreatic beta cells are cells involved in insulin release. Researchers examine responses in these and other experimental settings.
Albumin is a blood protein. A fatty-acid modification affects the molecule’s albumin binding and behavior. Receptor potency also depends on the assay used.
Dual Receptor Activation
| Receptor | Natural Hormone | Primary Effects | Tirzepatide Potency |
|---|---|---|---|
| GLP-1R | Glucagon-like Peptide-1 | Appetite suppression, delayed gastric emptying, insulin secretion, CV protection | Equal to native GLP-1 |
| GIPR | Glucose-dependent Insulinotropic Polypeptide | Insulin sensitization, adipose tissue modulation, lipid metabolism, bone preservation | ~5x more potent than native GIP |
What does the evidence show?
SURPASS and SURMOUNT include several human trials. A direct comparison tests compounds within the same study. SURPASS-2 is one such comparison with semaglutide.
Other percentages in the table come from different populations and endpoints. HbA1c is a measure related to average blood glucose. AHI measures breathing disturbances during sleep.
Read each numerical result in its original study. It is not an expected result for a laboratory reagent. Trial status descriptions may also become outdated.
Major Tirzepatide Clinical Programs
| Trial | Population | Key Finding | Status |
|---|---|---|---|
| SURMOUNT-1 | Obesity/overweight (no T2D) | 22.5% mean weight loss at 72 weeks (15mg) | Completed ✓ |
| SURMOUNT-2 | Obesity/overweight + T2D | 15.7% weight loss + HbA1c reduction | Completed ✓ |
| SURMOUNT-3 | Obesity + intensive lifestyle + tirzepatide | Combined approach amplified results | Completed ✓ |
| SURMOUNT-4 | Weight maintenance after initial loss | Sustained weight loss with continued treatment | Completed ✓ |
| SURPASS 1-6 | Type 2 diabetes | Superior HbA1c and weight vs. all comparators | Completed ✓ |
| SURPASS-CVOT | T2D + established CVD | Cardiovascular outcomes | Ongoing — 2026 readout expected |
| SURMOUNT-OSA | Obesity + obstructive sleep apnea | Significant AHI reduction | Completed ✓ |
Landmark Results
SURMOUNT-1 (NEJM, 2022)
22.5% mean body weight reduction at 72 weeks with tirzepatide 15mg vs. 3.1% with placebo. 36.2% of patients lost ≥25% of body weight. The largest weight loss ever achieved by a pharmaceutical in a Phase 3 obesity trial at that time.
SURPASS-2 (NEJM, 2021)
Tirzepatide 15mg reduced HbA1c by 2.46% vs. 1.86% for semaglutide 1mg in head-to-head comparison. Weight loss was also significantly greater with tirzepatide (12.4 kg vs. 6.2 kg). The first trial to demonstrate superiority over semaglutide.
SURMOUNT-OSA (NEJM, 2024)
Tirzepatide reduced obstructive sleep apnea severity (AHI) by up to 63%, with 40-50% of patients achieving disease resolution. This was the first demonstration that a metabolic medication could effectively treat sleep apnea.
Tirzepatide vs. Semaglutide vs. Retatrutide
SURPASS-2 provides direct evidence under its specific conditions. Comparisons with unrelated obesity trials are indirect. They cannot establish a universal ranking.
Cardiovascular risk markers differ from cardiovascular outcomes. A change in blood pressure is not the same as a measured change in heart attacks. Safety and tolerability also require matched comparisons.
| Property | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Max Weight Loss | ~16.9% (STEP 1) | ~22.5% (SURMOUNT-1) | ~28.7% (TRIUMPH-4) |
| Head-to-Head vs. Sema | Reference | Superior (SURPASS-2) | Not directly compared |
| GI Tolerability | Baseline | Better at equivalent weight loss | Similar to semaglutide |
| Cardiovascular Proof | SELECT: 20% MACE reduction ✓ | SURPASS-CVOT: pending | TRIUMPH-3: pending |
| Liver Fat Reduction | Moderate | Strong | Strongest (glucagon-driven) |
| FDA Status | Approved (multiple) | Approved (T2D + obesity) | Investigational (~2027) |
| Sleep Apnea | STEP-HFpEF (partial data) | SURMOUNT-OSA: 63% AHI reduction ✓ | TRIUMPH-1: pending |
| Key Advantage | Deepest evidence (CV + renal) | Best efficacy/tolerability ratio | Most weight loss; energy expenditure |
What are the limits of the safety evidence?
The clinical programs report digestive adverse events and other safety findings. Their frequency depends on the population and study conditions. This evidence concerns tested medicines.
GIP activity does not guarantee fewer adverse effects in every setting. Do not infer a research vial’s safety from a trial summary. This page provides no treatment schedule.
What questions remain for future research?
Researchers continue to examine the contribution of GIP activity. Mechanistic questions remain separate from clinical comparisons. A hypothesis about fat-cell biology needs direct experimental support.
Future multi-receptor studies can compare defined constructs and endpoints. Similar receptor activity does not make two products identical. Clinical status should be checked against current primary sources.
Frequently Asked Questions
What is tirzepatide?
How does tirzepatide differ from semaglutide?
What is the maximum weight loss with tirzepatide?
Does tirzepatide have cardiovascular benefits?
What are the side effects of tirzepatide?
Is tirzepatide FDA-approved?
What does GIP agonism actually do?
References
- [1] Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022;387:205-216.
- [2] Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM. 2021;385:503-515.
- [3] Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024;391:1919-1930.
- [4] Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021;12(1):143-157.
- [5] Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
- [6] Eli Lilly. Zepbound (tirzepatide) Prescribing Information. FDA. 2023.
